5 big analyst AI moves: Apple lifted to Buy, AI chip bets reassessed
Introduction & Market Context
Orion Oyj B (HEL:ORNBV) released its second-quarter and half-year 2025 financial results on July 18, showcasing exceptional growth across all business segments. The Finnish pharmaceutical company’s stock responded positively, rising 4.01% to €68.70 following the announcement, approaching its 52-week high of €69.10.
The strong performance builds on momentum established in Q1, when the company reported 15% revenue growth. Q2 results show further acceleration, with growth rates nearly doubling across key metrics compared to the first quarter.
Quarterly Performance Highlights
Orion reported substantial growth in Q2 2025, with net sales reaching €416.5 million, a 26.9% increase from €328.2 million in Q2 2024. Operating profit surged 58.9% to €104.6 million, compared to €65.8 million in the same period last year. The operating profit margin expanded significantly to 25.1% from 20.1% in Q2 2024.
As shown in the following financial highlights chart:
The company’s operating cash flow per share nearly tripled, increasing 189.7% to €0.57 compared to €0.20 in Q2 2024, demonstrating strong operational efficiency and improved working capital management.
For the first half of 2025, Orion’s net sales grew 21.1% to €771.0 million, while operating profit increased 49.8% to €182.5 million, resulting in an operating profit margin of 23.7%, up from 19.1% in H1 2024.
Detailed Financial Analysis
The primary growth driver continues to be Orion’s Innovative Medicines segment, particularly Nubeqa® (darolutamide), which saw sales more than double in Q2 2025 to €140.1 million from €71.6 million in Q2 2024. Overall, the Innovative Medicines segment grew 83.1% in Q2 and 77.8% in H1 2025.
The following chart illustrates the dramatic growth trajectory of Nubeqa® sales:
A detailed breakdown of net sales changes reveals that Innovative Medicines contributed €66.5 million to the overall sales increase, followed by Branded Products (€9.4 million), Generics and Consumer Health (€8.5 million), and Animal Health (€6.9 million). Only Fermion showed a slight decline of €2.1 million.
The operating profit bridge demonstrates that sales volume growth (€30.1 million) and other operating income and expenses (€22.0 million) were the main contributors to profit improvement, partially offset by changes in prices, COGS, and product mix (€14.5 million).
Orion’s top 10 products by net sales in H1 2025 were led by Nubeqa® at €231.6 million (+91.2%), followed by the Easyhaler® product portfolio at €88.9 million (+9.5%) and Entacapone products at €46.3 million (+7.1%). The company’s sales distribution shows Innovative Medicines now representing 35% of total sales, followed by Branded Products (32%), Generics and Consumer Health (20%), Animal Health (9%), and Fermion (4%).
Strategic Initiatives & Pipeline
Orion highlighted several strategic developments in its presentation, including FDA approval and CHMP recommendation for darolutamide + ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC), which should further drive Nubeqa® sales. Additionally, MSD is expanding the opevesostat program to women’s cancers, potentially opening new markets.
The company’s clinical development pipeline continues to advance, with Orion’s first biologics expected to enter clinical phase in the next 12-24 months. The pipeline includes multiple compounds in various stages of development across different therapeutic areas.
Orion also announced new and extended license agreements with Glykos, Shilpa, and Criceto, strengthening its partnership strategy. The company noted that the Easyhaler® product portfolio’s peak sales potential is expected to exceed €300 million in annual sales, representing significant future growth potential.
In line with global sustainability trends, Orion announced that its climate targets have been validated by the Science Based Targets initiative (SBTi), committing to reduce absolute scope 1 and 2 greenhouse gas emissions by 70% by 2030 from a 2023 base year.
Forward-Looking Statements
Following the strong first-half performance, Orion provided an outlook for 2025, projecting net sales between €1,630-1,730 million and operating profit between €400-500 million. This guidance, issued on July 9, 2025, represents a significant improvement over 2024 results and reflects confidence in continued growth across all business segments.
The company’s Q2 performance puts it on a solid trajectory to meet or potentially exceed these targets, with H1 2025 net sales already reaching €771.0 million, or approximately 45% of the midpoint of the full-year guidance. Similarly, H1 operating profit of €182.5 million represents about 41% of the midpoint of the full-year target, with historically stronger performance typically occurring in the second half of the year.
Orion has scheduled its next financial announcements, with the Interim Report for Q3 2025 due on October 28, 2025, and the Financial Statement Release for 2025 scheduled for February 12, 2026.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.